Physician profile
Michael G Burry
NPI 1447256821
$6,860.27
in general payments reported to CMS, 2019-2025
43 companies · $1,322 in 2025
The $1,322 reported for 2025 was more than what 94% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,456 · 2020: $950 · 2021: $1,152 · 2022: $588 · 2023: $633 · 2024: $759 · 2025: $1,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,713.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,012.71 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $817.17 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $523.19 | 2019-2025 | Vraylar, Qulipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $488.70 | 2023-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $463.49 | 2019-2025 | Jardiance |
| Amgen INC. | $449.23 | 2019-2024 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $381.95 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $370.12 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $222.46 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $192.12 | 2019-2023 | |
| Novo Nordisk INC | $191.66 | 2019-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $169.86 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $151.00 | 2019-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Eisai INC. | $144.64 | 2020-2022 | |
| Horizon Therapeutics Plc | $131.10 | 2019 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Burry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.